Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cardioprotection via Endothelial Extracellular Vesicles in a Human Heart-on-Chip Ischemia-Reperfusion-Injury Model

ABSTRACT: We have mapped and analyzed the protein content of extracellular vesicles isolated from HUVECs (EEVs). Several groups of cardioprotective proteins were detected, as well as proteins related to various metabolic processes and response to stress. We have tested the effect of these EEVs on human stem cell- derived cardiomyocytes (hCMS) experiencing ischemia reperfusion injury (IRI). We have demonstrated the EEV treatment reduced cell death following IRI, and preserved contractile function. The effect depended on EEVs internalization in hCMS. We have compared protein expression profiles of hCMs treated and untreated with EEVs, under normal conditions and following IRI. We show that EEVs induce changes in the protein expression profiles of normal hCMs. The changes are related to various transcriptional and metabolic processes and localized in mainly in the nucleus and mitochondrion. After induction of IRI the differences between the EEV-treated and untreated groups are enhanced with a larger amount of differentially expressed proteins, with the most significant changes in metabolic processes and binding activity.

INSTRUMENT(S): Orbitrap Fusion, LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Kevin Kit Parker

PROVIDER: MSV000085448 | MassIVE | Tue May 19 12:30:00 BST 2020

SECONDARY ACCESSION(S): PXD019299

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Circ3302 normal and up-regulated groups in HUVECs

| PRJNA793389 | ENA

HUVEC Gene Regulation by Histidine-Rich Glycoprotein

Project description:HRG is a 75kDa heparin-binding protein non to extert gene regultaion changes on macropahges. To assess the effect of HRG on Enodothelial Cell gene regulation Human Umbilical Vein Endothelial Cells (HUVECs) were treated with Histidine-Rich Glycoprotein (HRG) 24 hour treatment with HRG. and examined for gene regulation changes versus untreated HUVECs after 6 and

2015-03-12 | GSE66768 | GEO

MicroRNA signature of young and replicative senescent human umbilical vein endothelial cells (HUVECs)

Project description:MicroRNAs regulate various cellular processes. While several genes associated with replicative senescence have been described in endothelial cells, miRNAs that regulate these genes remain largely unknown. The present study was designed to identify miRNAs associated with replicative senescence and their target genes in HUVECs. We have employed Agilent Human MicroRNAs microarray platform to evaluate the expressions of 866 human miRNAs and 89 human viral miRNAs, based on Sanger miRNA database release 12.0 miRNA expression profiles were established for young and replicative senescent HUVECs

2013-04-05 | E-GEOD-37092 | biostudies-arrayexpress

Gene signature of young and replicative senescent human umbilical vein endothelial cells (HUVECs)

Project description:MicroRNAs regulate various cellular processes. While several genes associated with replicative senescence have been described in endothelial cells, miRNAs that regulate these genes remain largely unknown. The present study was designed to identify miRNAs associated with replicative senescence and their target genes in HUVECs. Gene profiling was established using the same RNA input as that used for miRNA profiing. We have employed Agilent Whole Human Genome microarray platform to evaluate the expressions of 19,596 human genes . Gene expression profiles were established for young and replicative senescent HUVECs

2013-04-05 | E-GEOD-37091 | biostudies-arrayexpress

DNAJA1 KO on HUVECs with heat stress

Project description:HS-induced proteome changes in WT and DNAJA1-KO cells were quantified using label free-based quantitative proteomic analysis. Four groups:wild type HUVECs group, DNAJA1 knockout HUVECs group, WT HUVECs with heat stress group, DNAJA1 knockout HUVECs with heat stress group,were conducted label free-based quantitative proteomic analysis to detect the mechanism of DNAJA1's protective effects on heat stress.

2024-03-26 | PXD043512 | Pride

Fullerene treatment of HUVECs

Project description:Control untreated versus fullerene-treated HUVECs Keywords: nanomaterial treatment

2005-09-27 | GSE3364 | GEO

Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients

Project description:1. Primary Endpoints * Biomarker data suggestive of regorafenib-mediated inhibition of the RAS-RAF- MEK-ERK signal transduction pathway,of various tyrosine kinase receptors and/or of angiogenesis. * Evaluation of potential relationships between biomarker data and clinical activity. * Evaluation of a novel biomarker technology (Prometheus COPIA platform) 2. Secondary Endpoints * Biomarker data suggestive of regorafenib-mediated effects on circulating rare cells. * Comparison of tumor genetic profiles obtained using DNA isolated from plasma, tumor biopsies and circulating tumor cells. * Patient safety data * Pharmacokinetics of regorafenib * Changes in tumor metabolic activity as measured by PET CT scan (optional)

| 2094187 | ecrin-mdr-crc

Analysis of transcriptional profiles in Saccharomyces cerevisiae exposed to bisphenol A

Project description:We analyzed genome-wide transcriptional profiles of Saccharomyces cerevisiae BY4742 strain in response to BPA, focusing on two exposure scenarios: (i) low-observed-effect concentration (<10% inhibition) to examine chronic effect of BPA on yeast population, and (ii) high-inhibitory concentration (>70% inhibition) to study acute effect. Initially, yeast cells were exposed to various concentrations of BPA. 50 mg/L and 300 mg/L BPA were determined as low-observed-effect concentration and the high-inhibitory concentration, respectively. Transcriptional profiles indicated that 81 genes were repressed and 104 genes were induced in response to 50 mg/L BPA. On the other hand, in 300 mg/L BPA exposure, 378 genes were down-regulated, while 606 genes were significantly up-regulated. Our data showed that there were similar processes affected by both concentrations such as mitochondria, nucleobase-containing small molecule metabolic process, transcription from RNA polymerase II promoter, and mitotic cell cycle and associated processes. However, different modes of actions of the BPA were found between two concentrations. 300 mg/L BPA exposure showed severe effects on the processes by repressing or inducing several genes or total mechanisms with high level of expression changes, while 50 mg/L BPA exposure changed the expression of some important genes with low level of expression changes in the processes. These results suggest that yeast cells respond via different ways to the different concentrations of BPA at transcriptomic level.

2018-10-19 | GSE74177 | GEO

lncRNA and mRNA expression of HUVECs under H/R and normal conditions

Project description:To have a global view of transcriptional change of hypoxia/reoxygenation (H/R) condition compared with normal condition, we collected human umbilical vein endothelial cells (HUVECs) from both conditions. The expression profiles of HUVECs were detected by microarray, and two conditions were compared to detect significantly changed lncRNAs and mRNAs.

2022-06-15 | GSE193047 | GEO

Expression data: Venous malformation-causative TIE2-mutations mediate an AKT-dependent decrease in PDGFB

Project description:Comparison of transcriptional profiles of human umbilical vein endothelial cells (HUVECs) expressing wild-type vs. VM-causative mutant forms of TIE2/TEK. The effects of the most common Venous Malformation-causative mutations in the endothelial cell tyrosine kinase receptor: R849W and L914F, were tested. 743 genes were differentially expressed across the four groups. The 80 genes distinguishing between L914F and wild-type TIE2-expressing HUVECs were analyzed in greater detail.

2013-06-04 | GSE46684 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data